Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Rapport Therapeutics, Inc. Common Stock (RAPP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: RAPP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $35
1 Year Target Price $35
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.43% | Avg. Invested days 20 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 417.17M USD | Price to earnings Ratio - | 1Y Target Price 35 |
Price to earnings Ratio - | 1Y Target Price 35 | ||
Volume (30-day avg) 5 | Beta - | 52 Weeks Range 6.43 - 29.74 | Updated Date 06/30/2025 |
52 Weeks Range 6.43 - 29.74 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.82 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.89% | Return on Equity (TTM) -33.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 139627053 | Price to Sales(TTM) - |
Enterprise Value 139627053 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 36497600 | Shares Floating 14942464 |
Shares Outstanding 36497600 | Shares Floating 14942464 | ||
Percent Insiders 6.4 | Percent Institutions 105.23 |
Analyst Ratings
Rating 3 | Target Price 35 | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Rapport Therapeutics, Inc. Common Stock
Company Overview
History and Background
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing precision medicines for neurological disorders. Founded in 2022, it aims to transform the lives of patients suffering from conditions such as epilepsy, chronic pain, and other central nervous system (CNS) disorders by selectively targeting the root causes of these diseases.
Core Business Areas
- Drug Discovery and Development: Focuses on identifying and developing novel drug candidates that selectively modulate specific neuronal circuits involved in neurological disorders.
- Precision Medicine Approach: Utilizes advanced technologies and a deep understanding of neurobiology to develop therapies that target the underlying causes of neurological diseases in specific patient populations.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates in patients with neurological disorders.
Leadership and Structure
Rapport Therapeutics has a leadership team with experience in drug discovery, development, and commercialization in the biotechnology industry. The company is structured around research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- RAP-219: A selective neuronal Kv7.2/7.3 channel agonist being developed for the treatment of drug-resistant focal epilepsy. The drug is currently in Phase 1 clinical trials. Competitors are companies developing anti-epileptic drugs such as UCB, SK Biopharmaceuticals, and Eisai Co.
- RAP-198: A selective neuronal Kv7.2/7.3 channel agonist is being developed for chronic pain. The drug is currently in Phase 1 clinical trials. Competitors are companies developing pain management drugs such as Pfizer, Eli Lilly, and Novartis.
Market Dynamics
Industry Overview
The neurological disorders market is large and growing, driven by an aging population and increasing prevalence of conditions such as epilepsy, Alzheimer's disease, and chronic pain. There is a high unmet need for more effective and targeted therapies.
Positioning
Rapport Therapeutics is positioned as a precision medicine company focused on developing novel therapies for neurological disorders. Its selective approach and focus on specific neuronal circuits offer a potential competitive advantage.
Total Addressable Market (TAM)
The TAM for neurological disorder therapies is estimated to be in the billions of dollars. Rapport is positioned to capture a significant portion of this market through its targeted therapies, though this is highly dependent on successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Precision medicine approach
- Strong scientific team
- Focus on unmet needs in neurological disorders
- Proprietary platform for drug discovery
Weaknesses
- Early-stage clinical development
- High risk of clinical trial failure
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on successful partnering or fundraising
Opportunities
- Potential for breakthrough therapies in neurological disorders
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas within neurology
- Advancements in precision medicine technologies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and approval delays
- Clinical trial failures
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- UCB (UCBJF)
- SK Biopharmaceuticals (326030.KS)
- Eisai Co. (ESALY)
- Pfizer (PFE)
- Eli Lilly (LLY)
- Novartis (NVS)
Competitive Landscape
Rapport Therapeutics competes with established pharmaceutical companies and other biotechnology firms in the neurological disorders market. Its focus on precision medicine and selective targeting of neuronal circuits differentiates it from some competitors, but clinical trials and regulatory approval are key hurdles.
Growth Trajectory and Initiatives
Historical Growth: Not applicable, as it's an early stage company.
Future Projections: Future growth is contingent on positive clinical trial results and successful commercialization of its drug candidates. Analyst estimates depend on regulatory approvals and market uptake.
Recent Initiatives: Recent initiatives include advancing RAP-219 and RAP-198 through Phase 1 clinical trials, expanding the pipeline of drug candidates, and strengthening the scientific team.
Summary
Rapport Therapeutics is an early-stage biotech company with a promising precision medicine approach targeting neurological disorders. Its strengths lie in its scientific expertise and innovative drug discovery platform. However, the company faces significant risks associated with clinical trials and competition. Successful clinical development and strategic partnerships will be crucial for its future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rapport Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2024-06-07 | CEO, President, Treasurer & Director Mr. Abraham N. Ceesay M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 69 | Website https://www.rapportrx.com |
Full time employees 69 | Website https://www.rapportrx.com | ||
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.